Sickle Cell Anemia
Rare Diseases
1
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GenentechRanibizumab
Clinical Trials (1)
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Start: Jan 2010Est. completion: Jun 20110
N/AWithdrawn
Related Jobs in Rare Diseases
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
8m ago
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
8m ago
Director, Clinical Development Operations Program Lead
Stoke Therapeutics
Bedford, Massachusetts, United States
18m ago
$236K - $260K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
12h ago
From $130K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
Somerville, Massachusetts, United States
12h ago
Ultra-Rare Area Business Leader – Northwest
Novartis
Field Sales (USA)
Yesterday
$168K - $312K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space